Gottlieb tackles speculators, FDA transparency and the R&D gold standard in a last round of queries ahead of confirmation vote
Fielding a final barrage of written questions from a group of skeptical Democratic US Senators ahead of today’s committee vote on Scott Gottlieb’s nomination as head of the FDA, the nation’s likely next Commissioner of Food and Drugs vowed to square off against financial speculators who are gaming the system to charge high prices, reaffirmed his unwavering support for the country’s gold standard on drug development and reviews and called for publishing most of what the agency’s CRLs say about regulators’ reasons for rejecting a marketing application.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.